REG - Biofrontera AG - Private Placement <Origin Href="QuoteRef">B8FGn.DE</Origin>

Biofrontera AGAnnouncement

16/02/2016 14:00

RNS Number : 2324P
Biofrontera AG
16 February 2016
Biofrontera AG 
("Biofrontera" or the "Company")
Private Placement
Leverkusen, Germany, February 16, 2016 - The Management Board of Biofrontera AG (FSE: B8F) has resolved on 12 February 2016, with the approval of the Supervisory Board, to increase the registered share capital of the Company by up to EUR2,357,384 from authorized capital by issuing up to 2,357,384 new no-par registered shares ("New Shares"). The shareholders' subscription right is excluded. The New Shares were offered to selected institutional investors at an issue price of EUR1.90 per New Share, for a total issue price of EUR4,479,029.60. All shares were successfully placed today.
The net proceeds of approx.EUR4.4 million will be used to cover the operational expenses of the Company and the further development of marketing the Company's main product Ameluz. Currently, Ameluz is approved for the treatment of actinic keratosis in the EU. With the proceeds from this issue, the Company intends to support the regulatory approval and commercialization in the US as well as the extension of the European approval of Ameluz for treatment of basal cell carcinoma.
The Management Board
Ends 
Enquiries, please contact: 
Biofrontera AG 
Thomas Schaffer, Chief Financial Officer
+49 (0) 214 87 63 2 0 
press@biofrontera.com 
www.biofrontera.com 
IR Germany: Brainwell Asset Solutions 
Jrgen Benker 
+49 (0) 152 08931514 
Nomad and Broker: Shore Capital 
Bidhi Bhoma / Toby Gibbs 
+44(0) 20 7408 4090 
IR UK: Seton Services 
Toni Vallen 
+44(0) 20 7729 0805 
Financial PR: Gable Communications 
John Bick / Justine James 
+44(0) 20 7193 7463 
+44 (0)7872 061007 
Background:
Biofrontera Group (FSE/AIM: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development, sale and distribution of drugs and medical cosmetics for the care and treatment of skin diseases. Biofrontera's most important product is Ameluz, a prescription drug which is approved in Europe for the treatment of mild and moderate actinic keratosis (superficial skin cancer) with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up company to obtain centralised approval for a drug it has developed itself. The company also plans for Ameluz to be approved for basal cell carcinoma and is currently preparing for approval in other countries, especially in the largest pharmaceutical market in the world, the United States. 
The company also markets the Belixos dermatological range of cosmetics. Belixos products, a cream, a gel and a scalp tonic, contain combinations of active substances extracted from plants, relieve itching and redness and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. The Belixos Protect, a daily skincare for sun-damaged skin, complements this dermo-cosmetic line. All products are available through Amazon.
The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lbbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.
www.biofrontera.com
This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements. 

This information is provided by RNS
The company news service from the London Stock Exchange
  END
MSCUNVORNNAUAAR